Related Experiment Video
Updated: Apr 11, 2026

Computed Tomography-guided Time-domain Diffuse Fluorescence Tomography in Small Animals for Localization of Cancer Biomarkers
Published on: July 17, 2012
αvβ3 integrin-targeted IR-820 dye-based small molecule probe for fluorescence imaging of tumor
Xinzhu Yuan1, Yuyao Zhang1, Jigao Xuan1
1The Education Ministry Key Lab of Resource Chemistry, Joint International Research Laboratory of Resource Chemistry, Ministry of Education, Shanghai Frontiers Science Center of Biomimetic Catalysis, and Shanghai Key Laboratory of Rare Earth Functional Materials, College of Chemistry and Materials Science, Shanghai Normal University, 100 Guilin Road, Shanghai 200234, China.
Abstract:
Owing to its advantages of high sensitivity, high specificity, and real-time detection capabilities, fluorescence molecular imaging techniques, such as near-infrared (NIR) fluorescence imaging, have been used to real-time intraoperative navigation in oncological surgery. Despite a variety of NIR fluorescent probes have been developed for tumor detection in biological field, just limited amount of these probes including the 5-aminolevulinic acid, fluoresceine, methylene blue and pafolacianine were approved by FDA for clinical use. And only pafolacianine has the tumor target property. Herein, we developed a near-infrared fluorescent probe IR-820-cRGD for in vivo tumor imaging. This probe integrates the near-infrared dye IR-820 with a cyclic peptide cRGD that can bind to the integrin αvβ3 receptor overexpressed on the surface of tumor cells, thus enabling the probe specifically accumulate at the tumor site. The results suggested that both the MDA-MB-231 cell line and tumor regions of nude mouse tumor models exhibited significantly higher fluorescence intensity compared to the normal cells or tissues. This demonstrates the probe's capability for precise tumor localization with low background signal, offering potential for early tumor diagnosis and therapeutic applications such as fluorescence-guided surgery.

